| Catalog No. | AV974024 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality | Polyclonal |
|---|
| Immunogen | Avelumab |
|---|
| Target | Rabbit polyclonal to Bavencio. |
|---|
| Specificity | The product is specific for Avelumab. This antibody serves as an excellent positive control for Avelumab immunogenicity (ADA) assays. |
|---|
| Purification | Purified by antigen affinity column. |
|---|
| Accession | 1537032-82-8 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
|---|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
|---|
| Background | Avelumab with trade name Bavencio, is an FDA-approved drug to treat Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by Avelumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as
|
|---|
| Note | For research use only. |
|---|
